PD168393|cas 194423-15-9|DC Chemicals

Cas No.:	194423-15-9
Chemical Name:	PD168393
Synonyms:	PD 168393;N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide;N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-propenamide;4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline;AC1L1IRY;AC1Q26CC;N-(4-(3-bromophenylamino)quinazoline-6-yl)acrylamide;N-[4-[(3-bromophenyl)-amino]-quinazolin-6-yl]-acrylamide;N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]-acrylamide;n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide;nchembio866-comp2;PD-168393;SureCN2680536;N-(4-((3-Bromophenyl)amino)quinazolin-6-yl)acrylamide;2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-;PD168393;3R996Y9T0I;C17H13BrN4O;N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide;2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-;N;4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-propenamide;BDBM4567;s7039;SCHEMBL2680536;NCGC00386260-01;CHEMBL285063;PD 168393 [WHO-DD];AC-32813;N-(4-(3-Bromophenylamino)quinazolin-6-yl)acrylamide;AKOS027337569;PD168393?;N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide;4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline;MFCD02179207;3968-03-4;NCGC00386260-02;CHEBI:131504;DTXSID80274444;HMS3652F18;SW218184-2;BCP07986;J-012594;DA-43376;PD168393, >=98% (HPLC);CCG-268278;EX-A808;NS00068483;HSCI1_000120;HTUBKQUPEREOGA-UHFFFAOYSA-N;CS-5723;4-anilinoquinazoline deriv. 2;BMC163482 Compound 1;SB19366;Q26998221;AS-67687;194423-15-9;F13662;HY-13896;N-[4-[(3-bromophenyl)amino]quinazolin-6-yl]acrylamide;DB07662;UNII-3R996Y9T0I;BRD-K17702546-001-03-2
SMILES:	BrC1=CC=CC(=C1)NC1=C2C=C(C=CC2=NC=N1)NC(C=C)=O
Formula:	C₁₇H₁₃BrN₄O
M.Wt:	369.215322256088
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

PD168393 is an potent, cell-permeable, irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773, inactive against insulin, PDGFR, FGFR and PKC. target: EGFRIC 50: 0.7 nM [1](1) PD 168393 inhibite EGFr autophosphorylation in A431 human epidermoid carcinoma cells with >9-fold greater potency than PD 174265.[1](2) PD 168393 decrease the production of TNF-α and phosphrylation of ERK1/2 and p38 induced by LPS in cardiomyocytes.[2](3) PD168393 completely inhibits AKT and ERK phosphorylation at concentrations as low as 0.03 umol/L.[3](4) PD168393 could induce apoptosis and inhibit cell growth in ErbB2 positive lung and breast cancer cell lines.[3](5) PD168393 disrupted MEK1/p44/42 ERK signaling in HaCaT cells as determined by inhibition of phospho-p44/42 ERK. [4]

Cat. No.	Product name	Field of application
DC70520	JBJ-09-063	JBJ-09-063 is a potent, mutant-selective allosteric EGFR inhibitor against EGFR L858R, T790M and C797S mutations, with IC50 of <0.1 nM for recombinant EGFR L858R/T790M kinase domain.
DC40932	JCN037	JCN037 (JGK037) is non-covalent and BBB-penetrant EGFR tyrosine kinase inhibitor, with IC50 values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively.
DC7622	BIBX1382	BIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM).
DC12161	TAS6417	TAS6417 is an EGFR inhibitor and an efficacious drug candidate for patients with NSCLC, with IC50 values ranging from 1.1-8.0 nM.
DC10764	Theliatinib (HMPL-309)	Theliatinib (HMPL-309) is a novel small molecule, EGFR tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenesis activities.
DC5090	WZ4002	WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM; does not inhibit ERBB2 phosphorylation (T798I).
DC9775	WZ3146	WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I).
DC10519	SU 5214	SU 5214 is a modulator of tyrosine kinase signal transduction.
DC7078	AZD-8931(Sapitinib)	Sapitinib(AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively.
DC10479	RX518(CK-101:EGFR-IN-3)	RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations.